How much did Novocure achieve in EBIT for the current year?
In the current year, Novocure has achieved an EBIT of -165.7 M USD.
Novocure EBIT 2024
Novocure EBIT
-165.7 M USD
Ticker
NVCR
ISIN
JE00BYSS4X48
WKN
A140ML
In 2024, Novocure's EBIT was -165.7 M USD, a -28.84% increase from the -232.87 M USD EBIT recorded in the previous year.
The Novocure EBIT history
| YEAR | EBIT (undefined USD) |
|---|---|
| 2029e | - |
| 2028e | -100.47 |
| 2027e | -166.46 |
| 2026e | -171.58 |
| 2025e | -178.29 |
| 2024e | -165.7 |
| 2023 | -232.87 |
| 2022 | -89.5 |
| 2021 | -44.3 |
| 2020 | 30.4 |
| 2019 | -0.9 |
| 2018 | -33.7 |
| 2017 | -39.3 |
| 2016 | -108.9 |
| 2015 | -104 |
| 2014 | -80.2 |
| 2013 | -64.5 |
Novocure Revenue, EBIT, Net Income JE00BYSS4X48 · A140ML
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Novocure, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Novocure from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Novocure’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Novocure. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Novocure’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Novocure’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Novocure’s growth potential.
Novocure Revenue, EBIT and net profit per share
| Date | Novocure Revenue | Novocure EBIT | Novocure Net Income |
|---|---|---|---|
| 2029e | 1.14 B undefined | 0 undefined | 8.83 M undefined |
| 2028e | 963.59 M undefined | -100.47 M undefined | -94.93 M undefined |
| 2027e | 763.01 M undefined | -166.46 M undefined | -145.71 M undefined |
| 2026e | 692.89 M undefined | -171.58 M undefined | -151.38 M undefined |
| 2025e | 628.07 M undefined | -178.29 M undefined | -156.08 M undefined |
| 2024e | 591.99 M undefined | -165.7 M undefined | -148.48 M undefined |
| 2023 | 509.34 M undefined | -232.87 M undefined | -207.04 M undefined |
| 2022 | 537.8 M undefined | -89.5 M undefined | -92.5 M undefined |
| 2021 | 535 M undefined | -44.3 M undefined | -58.4 M undefined |
| 2020 | 494.4 M undefined | 30.4 M undefined | 19.8 M undefined |
| 2019 | 351.3 M undefined | -900,000 undefined | -7.2 M undefined |
| 2018 | 248.1 M undefined | -33.7 M undefined | -63.6 M undefined |
| 2017 | 177 M undefined | -39.3 M undefined | -61.7 M undefined |
| 2016 | 82.9 M undefined | -108.9 M undefined | -131.8 M undefined |
| 2015 | 33.1 M undefined | -104 M undefined | -111.6 M undefined |
| 2014 | 15.5 M undefined | -80.2 M undefined | -80.7 M undefined |
| 2013 | 10.4 M undefined | -64.5 M undefined | -77.4 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 10.4 M USD | -64.5 M USD | -77.4 M USD |
| 2014 | 15.5 M USD | -80.2 M USD | -80.7 M USD |
| 2015 | 33.1 M USD | -104 M USD | -111.6 M USD |
| 2016 | 82.9 M USD | -108.9 M USD | -131.8 M USD |
| 2017 | 177 M USD | -39.3 M USD | -61.7 M USD |
| 2018 | 248.1 M USD | -33.7 M USD | -63.6 M USD |
| 2019 | 351.3 M USD | -900,000 USD | -7.2 M USD |
| 2020 | 494.4 M USD | 30.4 M USD | 19.8 M USD |
| 2021 | 535 M USD | -44.3 M USD | -58.4 M USD |
| 2022 | 537.8 M USD | -89.5 M USD | -92.5 M USD |
| 2023 | 509.34 M USD | -232.87 M USD | -207.04 M USD |
| 2024e | 591.99 M USD | -165.7 M USD | -148.48 M USD |
| 2025e | 628.07 M USD | -178.29 M USD | -156.08 M USD |
| 2026e | 692.89 M USD | -171.58 M USD | -151.38 M USD |
| 2027e | 763.01 M USD | -166.46 M USD | -145.71 M USD |
| 2028e | 963.59 M USD | -100.47 M USD | -94.93 M USD |
| 2029e | 1.14 B USD | 0 USD | 8.83 M USD |
Novocure stock margins JE00BYSS4X48 · A140ML
The Novocure margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novocure. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novocure.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Novocure's sales revenue. A higher gross margin percentage indicates that the Novocure retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Novocure's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Novocure's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Novocure's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Novocure. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Novocure's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Novocure Margin History
| Novocure Gross margin | Novocure Profit margin | Novocure EBIT margin | Novocure Profit margin |
|---|---|---|---|
| 2029e | 74.81 % | 0 % | 0.77 % |
| 2028e | 74.81 % | -10.43 % | -9.85 % |
| 2027e | 74.81 % | -21.82 % | -19.1 % |
| 2026e | 74.81 % | -24.76 % | -21.85 % |
| 2025e | 74.81 % | -28.39 % | -24.85 % |
| 2024e | 74.81 % | -27.99 % | -25.08 % |
| 2023 | 74.81 % | -45.72 % | -40.65 % |
| 2022 | 78.65 % | -16.64 % | -17.2 % |
| 2021 | 78.54 % | -8.28 % | -10.92 % |
| 2020 | 78.46 % | 6.15 % | 4 % |
| 2019 | 74.78 % | -0.26 % | -2.05 % |
| 2018 | 67.71 % | -13.58 % | -25.63 % |
| 2017 | 68.59 % | -22.2 % | -34.86 % |
| 2016 | 51.87 % | -131.36 % | -158.99 % |
| 2015 | 37.76 % | -314.2 % | -337.16 % |
| 2014 | 35.48 % | -517.42 % | -520.65 % |
| 2013 | 31.73 % | -620.19 % | -744.23 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 31.73 % | -620.19 % | -744.23 % |
| 2014 | 35.48 % | -517.42 % | -520.65 % |
| 2015 | 37.76 % | -314.2 % | -337.16 % |
| 2016 | 51.87 % | -131.36 % | -158.99 % |
| 2017 | 68.59 % | -22.2 % | -34.86 % |
| 2018 | 67.71 % | -13.58 % | -25.63 % |
| 2019 | 74.78 % | -0.26 % | -2.05 % |
| 2020 | 78.46 % | 6.15 % | 4 % |
| 2021 | 78.54 % | -8.28 % | -10.92 % |
| 2022 | 78.65 % | -16.64 % | -17.2 % |
| 2023 | 74.81 % | -45.72 % | -40.65 % |
| 2024e | 74.81 % | -27.99 % | -25.08 % |
| 2025e | 74.81 % | -28.39 % | -24.85 % |
| 2026e | 74.81 % | -24.76 % | -21.85 % |
| 2027e | 74.81 % | -21.82 % | -19.1 % |
| 2028e | 74.81 % | -10.43 % | -9.85 % |
| 2029e | 74.81 % | 0 % | 0.77 % |
Novocure Aktienanalyse
What does Novocure do?
Novocure Ltd. is a global scientific-based company that was founded in Israel in 2000. Its focus was originally on researching and developing tumor therapies. Since then, Novocure has become one of the leading companies in cancer research and treatment, specializing in the development of innovative cancer therapies. The business model of Novocure is based on developing powerful and innovative treatment methods for a variety of cancer types, including brain, pancreatic, prostate, and lung cancer. The company is committed to developing new cancer treatments that improve the lives of patients and meet their needs. Novocure also offers a wide range of products, including several treatment options based on the use of electric fields. These electric fields can specifically target the tumor and inhibit cell division without damaging the surrounding healthy tissue. This innovative technology is also called "tumor therapeutic fields" (TTF). TTF is a non-invasive procedure that is able to destroy cancer cells and inhibit the growth of cancer cells using targeted radio waves. The company also has its own research and development department dedicated to the development of innovative cancer therapies. In collaboration with numerous leading medical experts and researchers worldwide, Novocure advances cancer treatment research and development, striving to improve the treatment of cancer patients worldwide. Novocure operates three main divisions: Onco-Support, Onco-Centers, and Medical Research. The Onco-Support division offers specialized services to patients, such as training on the use of TTF devices, assistance with insurance issues, facilitating access to TTF devices, and help with setting up TTF devices. The Onco-Centers division operates various clinics specialized in the treatment of skin and brain cancer. Here, patients can benefit from the use of TTF devices and receive this therapy from experienced specialists. The Onco-Centers also provide tailored support and counseling for the needs of patients. The Medical Research division of the company also conducts research and development activities in the field of cancer therapies. Here, new therapies and procedures for cancer treatment are explored and developed, with a particular focus on the application of TTF devices. The goal of this research is to develop innovative cancer treatments that improve the lives of cancer patients and give them hope for a better future. Overall, Novocure Ltd. is an innovative and customer-oriented company dedicated to the treatment of cancer patients. The company invests heavily in research and development to develop innovative therapies and products that meet the high needs of cancer patients. The use of TTF technology is a significant step in cancer treatment, and Novocure Ltd. is leading the global development in this regard. Novocure ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Novocure's EBIT
Novocure's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Novocure's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Novocure's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Novocure’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Novocure stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Novocure.
How has the EBIT of Novocure developed in recent years?
The EBIT of Novocure has increased by -28.844% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Novocure?
The EBIT of Novocure is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Novocure pay?
Over the past 12 months, Novocure paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Novocure is expected to pay a dividend of 0 USD.
What is the dividend yield of Novocure?
The current dividend yield of Novocure is .
When does Novocure pay dividends?
Novocure pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Novocure?
Novocure paid dividends every year for the past 0 years.
What is the dividend of Novocure?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Novocure located?
Novocure is assigned to the 'Health' sector.
Wann musste ich die Aktien von Novocure kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Novocure from 9/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/6/2024.
When did Novocure pay the last dividend?
The last dividend was paid out on 9/6/2024.
What was the dividend of Novocure in the year 2023?
In the year 2023, Novocure distributed 0 USD as dividends.
In which currency does Novocure pay out the dividend?
The dividends of Novocure are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Novocure
Our stock analysis for Novocure Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novocure Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.